Steven A. Weissman
VP & Head of CMCDr. Steven A. Weissman is VP & Head of CMC of Cognition Therapeutics, Inc. from July 2023. Before joining Cognition Therapeutics, Dr. Weissman was the director of chemical development at Lexicon Pharmaceuticals, where he was responsible for clinical supply and eventual global commercial manufacturing of telotristat etiprate. Earlier, he was director of process chemistry at J-Star Research and Concert Pharmaceuticals. During his tenure at Merck in manufacturing and process research roles, Dr. Weissman developed scalable chemical routes for over 30 clinical candidates and contributed to the commercial manufacturing routes of approved HIV therapies, Isentress and Crixivan. Dr. Weissman has co-authored 32 peer-reviewed research articles in scientific journals and is an inventor on 13 U.S. patents. In addition, he was a member of the editorial advisory board for the ACS journal, Organic Process Research & Development. Dr. Weissman earned a Bachelor of Arts in chemistry from the University of Vermont and a Doctor of Philosophy in chemistry from Tufts University. He conducted his post-doctoral training under Nobel laureate, Herbert C. Brown, at Purdue University.
Positions
- Company NameCognition Therapeutics, Inc.Stock CodeCGTXPositionVP & Head of CMCColleagues
- LRLisa RicciardiCEO, President & Director
- JAJack A. KhattarIndependent Chairman of the Board
- JBJohn Brendan DoyleChief Financial Officer
- AOAnthony O. CaggianoChief Medical Officer
- ACAnita CornetHead of Quality
- AGAaron Glenn Louis FletcherIndependent Director
- EBEllen B. RichstoneIndependent Director
- MGMichael GrundmanMember of Medical Advisory Board
